Alabama Board of Pharmacy

The Board conducted disciplinary hearings for several cases and held multiple executive sessions to deliberate on these disciplinary matters, as well as applicant cases and virtual requests. Following the deliberations, the Board voted on various applicant case motions to grant approval. Additionally, the Board met in an executive session to discuss the legal ramifications of pending litigation.

The board conducted a series of disciplinary case hearings and reviewed applicant appearances. During the session, the board moved into executive sessions to deliberate on specific disciplinary matters, review pending cases, and discuss potential litigation. Several motions were passed regarding disciplinary cases, including issuing letters of concern, corrective action plans, finding no violation, taking no further action, referring cases to federal or state authorities, and accepting a surrender. Additionally, the board heard multiple applicant appearance cases and made determinations regarding registration and virtual request denials.

The Board conducted a business meeting involving several regulatory and administrative agenda items. Presentations were heard regarding requests for various pharmacy permits, including off-site order entry and central fill authorizations. Reports were provided covering the Treasurer's financial overview, the Wellness Committee's current caseload, investigator activity including inspections and complaints, and the Secretary's report on topics such as GLP-1 medication compounding, naloxone access, legislative compliance audits, database migration, and fraud awareness. The Board addressed old business including rule amendments related to institutional pharmacies, private consultation areas, pharmacy technician roles, and collaborative practice. New business included a review of the fiscal year 2025 budget, clarification on pharmacists' authority to administer long-acting injectables and create prescription orders, and the creation of a workgroup for institutional centralized pharmacy services. The Board also entered executive session to discuss regulated party qualifications and pending litigation before voting on various case motions.

The board meeting covered several regulatory and administrative topics. Key discussions included the current FDA stance on compounding peptides, with a focus on which peptides are permissible for compounding and the requirement for pharmacists to adhere to United States Pharmacopeia (USP) standards as mandated by federal law. The board also received a treasurer's report detailing the fiscal year's revenue and operating expenses, as well as a wellness committee report regarding monitoring of health professionals.

The board meeting agenda includes presentations from a supervising pharmacist, a central fill request for a pharmacy, and a pending non-resident pharmacy permit. Reports will be provided by the treasurer, wellness committee, chief investigator, executive secretary, and attorney. Old business includes discussions on civil penalty schedules, holding public hearings for rule petitions, and reviewing updates on rulemaking, board governance, emergency dispensing, and travel requests. The board will also discuss a joint resolution regarding collaborative pharmacy practice under new business.